Ex­clu­sive: CSO George Yan­copou­los talks Re­gen­eron’s next chap­ter of ge­net­ics, weight loss drugs, and Alzheimer's

Last year
People
R&D

Fol­low­ing in­jec­tion side ef­fects, De­sign Ther­a­peu­tics to re­for­mu­late Friedre­ich's atax­ia drug, de­lay tri­al time­line

Last year
R&D

Alaunos’ run­way ends be­fore New Year's, as TCR biotech shrinks staff, seeks sale

Last year
People
R&D

Take­da spin­out Hill­e­Vax de­lays PhI­Ib norovirus topline da­ta un­til mid-2024 over pro­cess­ing lo­gis­tics

Last year
R&D

Re­vance touts first ther­a­peu­tic in­di­ca­tion for Botox ri­val Daxxi­fy in cer­vi­cal dys­to­nia

Last year
Pharma
FDA+

HHS ham­mers in­dus­try's at­tempt to de­lay new drug price ne­go­ti­a­tions

Last year
Pharma

Judge strikes down J&J talc unit's sec­ond bank­rupt­cy at­tempt over lack of 'fi­nan­cial dis­tress'

Last year
Pharma
Law

Am­gen, Hori­zon urge judge to up­hold con­sti­tu­tion­al­i­ty ar­gu­ments against FTC

Last year
Deals
Pharma

Arc­turus Ther­a­peu­tics hand­ed $115M from Japan­ese gov­ern­ment to de­vel­op pro­duc­tion site

Last year
Pharma
Manufacturing

Har­mo­ny looks to buy rare dis­ease drug de­vel­op­er in deal worth up to $200M

Last year
Deals
Pharma

Pfiz­er cel­e­brates ac­cel­er­at­ed win for po­ten­tial mul­ti­ple myelo­ma block­buster

Last year
Pharma
FDA+

Ra­dius Phar­ma sells off part of its roy­al­ties, mile­stones in breast can­cer drug Orser­du

Last year
Deals
Pharma

Am­gen takes a light­heart­ed ap­proach in lat­est Ote­zla cam­paign around mild-to-mod­er­ate pso­ri­a­sis

Last year
Pharma
Marketing

Ther­mo Fish­er Sci­en­tif­ic to trim staff by more than 200 at Flori­da site

Last year
People
Manufacturing

Fresh Tracks stops drug pipeline to save mon­ey as it keeps look­ing for an ex­it

Last year
R&D

Taysha rais­es $150M PIPE, shares sin­gle pa­tient da­ta on Rett syn­drome gene ther­a­py

Last year
Financing
R&D

Af­ter pa­tient death, FDA slaps clin­i­cal hold on ear­ly-stage AML tri­al study­ing 2sev­en­ty bio as­set

Last year
R&D

BioX­cel lays off 100 em­ploy­ees as it looks to change up its strat­e­gy

Last year
People
R&D

Roivant CEO hints at more deals shap­ing up as key Im­muno­vant da­ta loom

Last year
R&D
Pharma

FDA ex­tends re­view on Val­ne­va chikun­gun­ya vac­cine by three months

Last year
FDA+

Bio­gen's $7.3B deal for Rea­ta fol­lowed a bid­ding war with mys­te­ri­ous 'Par­ty A'

Last year
Deals
Pharma

FDA hands ap­proval to Janssen's BR­CA-pos­i­tive prostate can­cer com­bo tablet

Last year
Pharma
FDA+

In­cyte ax­es blood can­cer col­lab with Sy­ros

Last year
Deals
R&D

No­vo Nordisk and the fu­ture of obe­si­ty drugs; Ex­it Q&A with As­traZeneca's Mene Pan­ga­los; Il­lu­mi­na’s bad week; ...

Last year
Weekly
First page Previous page 296297298299300301302 Next page Last page
A service from the Financial Times